Deutsche Bank’s Gyre Therapeutics GYRE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $74K | Hold |
10,613
| – | – | ﹤0.01% | 3366 |
|
|
2025
Q4 | $74.9K | Sell |
10,613
-314
| -3% | -$2.42K | ﹤0.01% | 3383 |
|
|
2025
Q3 | $81.5K | Hold |
10,927
| – | – | ﹤0.01% | 3366 |
|
|
2025
Q2 | $80.3K | Buy |
+10,927
| New | +$95.3K | ﹤0.01% | 3325 |
|
|
2021
Q3 | – | Sell |
-25,991
| Closed | -$844K | – | 4511 |
|
|
2021
Q2 | $844K | Sell |
25,991
-9,363
| -26% | -$321K | ﹤0.01% | 2878 |
|
|
2021
Q1 | $1.34M | Buy |
35,354
+33,263
| +1,591% | +$1.52M | ﹤0.01% | 2480 |
|
|
2020
Q4 | $99K | Buy |
2,091
+476
| +29% | +$20.6K | ﹤0.01% | 3847 |
|
|
2020
Q3 | $53K | Sell |
1,615
-122
| -7% | -$4.78K | ﹤0.01% | 3861 |
|
|
2020
Q2 | $76K | Buy |
1,737
+457
| +36% | +$21.5K | ﹤0.01% | 3594 |
|
|
2020
Q1 | $42K | Sell |
1,280
-720
| -36% | -$33.1K | ﹤0.01% | 3631 |
|
|
2019
Q4 | $102K | Sell |
2,000
-1,340
| -40% | -$56.1K | ﹤0.01% | 3567 |
|
|
2019
Q3 | $122K | Sell |
3,340
-2,643
| -44% | -$142K | ﹤0.01% | 3451 |
|
|
2019
Q2 | $329K | Sell |
5,983
-10,664
| -64% | -$666K | ﹤0.01% | 3532 |
|
|
2019
Q1 | $1.01M | Buy |
16,647
+14,573
| +703% | +$936K | ﹤0.01% | 2983 |
|
|
2018
Q4 | $122K | Sell |
2,074
-1,529
| -42% | -$113K | ﹤0.01% | 4124 |
|
|
2018
Q3 | $291K | Buy |
3,603
+315
| +10% | +$25K | ﹤0.01% | 4063 |
|
|
2018
Q2 | $287K | Buy |
3,288
+1,195
| +57% | +$210K | ﹤0.01% | 4128 |
|
|
2018
Q1 | $405K | Buy |
2,093
+2,073
| +10,365% | +$387K | ﹤0.01% | 3829 |
|
|
2017
Q4 | $2K | Sell |
20
-27
| -57% | -$1.38K | ﹤0.01% | 4912 |
|
|
2017
Q3 | $1K | Sell |
47
-433
| -90% | -$13K | ﹤0.01% | 4824 |
|
|
2017
Q2 | $16K | Buy |
+480
| New | +$17.2K | ﹤0.01% | 4600 |
|
|
2016
Q3 | – | Sell |
-14
| Closed | -$2K | – | 5028 |
|
|
2016
Q2 | $2K | Hold |
14
| – | – | ﹤0.01% | 5089 |
|
|
2016
Q1 | $2K | Sell |
14
-17
| -55% | -$4.1K | ﹤0.01% | 5047 |
|
|
2015
Q4 | $10K | Sell |
31
-107
| -78% | -$42.1K | ﹤0.01% | 4920 |
|
|
2015
Q3 | $72K | Sell |
138
-135
| -49% | -$206K | ﹤0.01% | 4251 |
|
|
2015
Q2 | $598K | Sell |
273
-99
| -27% | -$198K | ﹤0.01% | 3291 |
|
|
2015
Q1 | $868K | Buy |
372
+153
| +70% | +$316K | ﹤0.01% | 2953 |
|
|
2014
Q4 | $452K | Buy |
219
+40
| +22% | +$77.1K | ﹤0.01% | 3744 |
|
|
2014
Q3 | $357K | Sell |
179
-59
| -25% | -$146K | ﹤0.01% | 3718 |
|
|
2014
Q2 | $843K | Buy |
238
+33
| +16% | +$108K | ﹤0.01% | 3079 |
|
|
2014
Q1 | $767K | Sell |
205
-4
| -2% | -$14.8K | ﹤0.01% | 3047 |
|
|
2013
Q4 | $681K | Sell |
209
-454
| -68% | -$1.79M | ﹤0.01% | 2892 |
|
|
2013
Q3 | $2.77M | Buy |
663
+69
| +12% | +$278K | ﹤0.01% | 2251 |
|
|
2013
Q2 | $2M | Buy |
+594
| New | +$2.26M | ﹤0.01% | 2222 |
|
Other funds holding GYRE
VCM
SS
VFT
VPM
Deutsche Bank's GYRE Position: Q1 2026 in Review
Deutsche Bank held its Gyre Therapeutics (GYRE) position steady in Q1 2026 at 10,613 shares worth $74K. The position accounts for ﹤0.01% of the portfolio, ranked #3366.
Deutsche Bank first reported a position in GYRE in Q2 2013 and has held it in 34 quarters since. The position peaked at $2.77M in Q3 2013. 56 funds tracked by Wall St. Rank hold GYRE as of Q1 2026.
- Deutsche Bank held 10,613 shares of Gyre Therapeutics worth $74K as of Q1 2026.
- Deutsche Bank left its Gyre Therapeutics share count unchanged in Q1 2026.
- Gyre Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #3366 holding.
- Deutsche Bank first reported a position in Gyre Therapeutics in Q2 2013 and has held it in 34 quarters since.
- Deutsche Bank's Gyre Therapeutics position peaked at $2.77M in Q3 2013.
- 56 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q1 2026.
Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.